What are the outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States?
In a 2018 Circulation study, Siontis et al. found that the outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States included a decreased risk of stroke or systemic embolism, lower risk of major bleeding, and lower mortality. The authors also noted that apixaban was associated with a higher risk of gastrointestinal bleeding compared to warfarin.